GNF-PF-1958 (CID 44582409) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(15)
 
 
Unspecified(36)
 
 
BioAssay Types:
Literature(47)
 
 
 
BioActivity Types:
EC50(2)
 
 
IC50(2)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 51    Data Row: 51   Total Pages: 2   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103631848]
IC50 0.003Cytotoxicity against human HCT116 cells [AID417514, Type: Literature]
View
2
[SID103631848]
MIC 0.01Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29212 by CLIS method [AID417512, Type: Literature]
View
3
[SID103631848]
MIC 0.01Antimicrobial activity against methicillin-resistant Enterococcus faecalis ATCC 35556 by CLIS method [AID417513, Type: Literature]
View
4
[SID103631848]
MIC 0.03Antimicrobial activity against methicillin-resistant Staphylococcus aureus L32 clinical isolate by CLIS method [AID417510, Type: Literature]
View
5
[SID103631848]
MIC 0.03Antimicrobial activity against methicillin-resistant Staphylococcus aureus L44 clinical isolate by CLIS method [AID417511, Type: Literature]
View
6
[SID103631848]
EC50 0.0737NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay [AID449703, Type: other]
View
7
[SID103631848]
IC50 0.5Cytotoxicity in human leukaemic CCRF-CEM cells. [AID43704, Type: Literature]
View
8
[SID103631848]
EC50 0.524NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay [AID449704, Type: other]
View
9
[SID103631848]
 Inhibition of methicillin-susceptible Staphylococcus aureus ATCC 29212 biofilm formation assessed as visible growth after 24 hrs [AID417529, Type: Literature]
View
10
[SID103631848]
 Inhibition of methicillin-susceptible Staphylococcus aureus ATCC 29212 biofilm formation assessed as concentration required to eradicate growth after 24 hrs [AID417530, Type: Literature]
View
11
[SID103631848]
 Inhibition of Enterococcus faecalis ATCC 35556 biofilm formation assessed as visible growth after 24 hrs [AID417531, Type: Literature]
View
12
[SID103631848]
 Inhibition of Enterococcus faecalis ATCC 35556 biofilm formation assessed as concentration required to eradicate growth after 24 hrs [AID417532, Type: Literature]
View
13
[SID103631848]
 Binding affinity to calf thymus DNA at 20 uM after 20 mins by UV spectrophotometer analysis [AID552124, Type: Literature]
View
14
[SID103631848]
 Inhibition of Staphylococcus aureus ATCC 29212 biofilm formation at MIC [AID417523, Type: Literature]
View
15
[SID103631848]
 Inhibition of Enterococcus faecalis ATCC 35556 biofilm formation at MIC [AID417524, Type: Literature]
View
16
[SID103631848]
CC50 10NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) [AID449705, Type: other]
View
17
[SID103631848]
 NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. [AID449706, Type: other]
View
18
[SID103631848]
 Binding affinity to calf thymus DNA assessed as change on melting temperature (Rvb = 78 degC) [AID552126, Type: Literature]
View
19
[SID103631848]
 Inhibition of methicillin-resistant Staphylococcus aureus L32 clinical isolate biofilm formation assessed as visible growth after 24 hrs [AID417525, Type: Literature]
View
20
[SID103631848]
 Inhibition of methicillin-resistant Staphylococcus aureus L32 clinical isolate biofilm formation assessed as concentration required to eradicate growth after 24 hrs [AID417526, Type: Literature]
View
21
[SID103631848]
 Inhibition of methicillin-resistant Staphylococcus aureus L44 clinical isolate biofilm formation assessed as visible growth after 24 hrs [AID417527, Type: Literature]
View
22
[SID103631848]
 Inhibition of methicillin-resistant Staphylococcus aureus L44 clinical isolate biofilm formation assessed as concentration required to eradicate growth after 24 hrs [AID417528, Type: Literature]
View
23
[SID103631848]
 In vivo antitumor activity was determined against B16 tumor cell lines in mice at dose of 0.03125 mg/kg administered intraperitoneally. [AID40740, Type: Literature]
View
24
[SID103631848]
 In vitro cytotoxicity against B16 tumor cell lines. [AID40736, Type: Literature]
View
25
[SID103631848]
 Inhibitory activity against growth of B16 mouse myeloma cell line was determined by MTT assay [AID39137, Type: Literature]
View
26
[SID103631848]
 Antimicrobial activity against methicillin-resistant Staphylococcus aureus L32 clinical isolate assessed as reduction in bacterial load at 2 X MIC over 24 hrs by time-kill assay [AID417515, Type: Literature]
View
27
[SID103631848]
 Antimicrobial activity against methicillin-resistant Staphylococcus aureus L44 clinical isolate assessed as reduction in bacterial load at 2 X MIC over 24 hrs by time-kill assay [AID417516, Type: Literature]
View
28
[SID103631848]
 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29212 assessed as reduction in bacterial load at 2 X MIC over 24 hrs by time-kill assay [AID417517, Type: Literature]
View
29
[SID103631848]
 Antimicrobial activity against Enterococcus faecalis ATCC 35556 assessed as reduction in bacterial load at 2 X MIC over 24 hrs by time-kill assay [AID417518, Type: Literature]
View
30
[SID103631848]
 Antimicrobial activity against methicillin-resistant Staphylococcus aureus L32 clinical isolate assessed as reduction in bacterial load at 4 fold MIC over 24 hrs by time-kill assay [AID417519, Type: Literature]
View
31
[SID103631848]
 Antimicrobial activity against methicillin-resistant Staphylococcus aureus L44 clinical isolate assessed as reduction in bacterial load at 4 fold MIC over 24 hrs by time-kill assay [AID417520, Type: Literature]
View
32
[SID103631848]
 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29212 assessed as reduction in bacterial load at 4 fold MIC over 24 hrs by time-kill assay [AID417521, Type: Literature]
View
33
[SID103631848]
 Antimicrobial activity against Enterococcus faecalis ATCC 35556 assessed as reduction in bacterial load at 4 fold MIC over 24 hrs by time-kill assay [AID417522, Type: Literature]
View
34
[SID103631848]
 Inhibitory activity against growth of HT-29 colon tumor cell line was determined by MTT assay [AID83754, Type: Literature]
View
35
[SID103631848]
 Percentage of apoptotic HT-29 cells after 24 H treatment with 10 ug/mL concentration of compound [AID83937, Type: Literature]
View
36
[SID103631848]
 In vitro cytotoxicity against P388 tumor cell lines. [AID152925, Type: Literature]
View
37
[SID103631848]
 In vivo antitumor activity was determined against P388 tumor cell lines in mice at dose of 0.03125 mg/kg administered intraperitoneally. [AID152928, Type: Literature]
View
38
[SID103631848]
 In vivo antitumor activity was determined against P388 tumor cell lines in mice at dose of 0.0625 mg/kg administered intraperitoneally. [AID152929, Type: Literature]
View
39
[SID103631848]
 In vivo antitumor activity was determined against P388 tumor cell lines in mice at dose of 0.125 mg/kg administered intraperitoneally. [AID152930, Type: Literature]
View
40
[SID103631848]
 In vivo antitumor activity was determined against P388 tumor cell lines in mice at dose of 0.25 mg/kg administered intraperitoneally. [AID153061, Type: Literature]
View
41
[SID103631848]
 In vivo antitumor activity was determined against P388 tumor cell lines in mice at dose of 1 mg/kg administered intraperitoneally. [AID153064, Type: Literature]
View
42
[SID103631848]
 Inhibitory activity against growth of PANC-1 tumor cell line was determined by MTT assay [AID154609, Type: Literature]
View
43
[SID103631848]
 In vitro cytotoxicity against SNU16 tumor cell lines. [AID200832, Type: Literature]
View
44
[SID103631848]
 Cytotoxicity against mouse P388 cells assessed as concentration required for 50% inhibition [AID318601, Type: Literature]
View
45
[SID103631848]
 Antimicrobial activity against Bacillus anthracis [AID399575, Type: Literature]
View
46
[SID103631848]
 Antiplasmodial activity against Plasmodium falciparum [AID399576, Type: Literature]
View
47
[SID103631848]
 In vivo antitumor activity was determined against B16 tumor cell lines in mice at dose of 0.0625 mg/kg administered intraperitoneally. (p<0.05) [AID40741, Type: Literature]
View
48
[SID103631848]
 In vivo antitumor activity was determined against B16 tumor cell lines in mice at dose of 0.25 mg/kg administered intraperitoneally. (p<0.05) [AID40742, Type: Literature]
View
49
[SID103631848]
 In vivo antitumor activity was determined against B16 tumor cell lines in mice at dose of 0.125 mg/kg administered intraperitoneally. (p<0.05) [AID40747, Type: Literature]
View
50
[SID103631848]
 In vivo antitumor activity was determined against B16 tumor cell lines in mice at dose of 1 mg/kg administered intraperitoneally. [AID40748, Type: Literature]
View